Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PHARBullishIndustry Newsnews

High materiality7/10

FDA Accepts sNDA for Lower-Dose Joenja in Young APDS Patients, Jan 2027

Sep 25, 2026, 11:31 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory milestones often re-rate biotech small/mid caps; this directly expands the patient population and potential revenue for Joenja, contingent on a Jan 2027 decision.

AI summary

What happened, with direct paths to the underlying reporting

Pharming said FDA accepted its sNDA to extend Joenja to younger, lighter children with APDS. Positive Phase III data in 4–11 y olds support a lower-dose regimen, and the Priority Review with a Jan 2027 PDUFA date could broaden the addressable patient pool and potential revenue for Joenja.

FDA accepts Joenja sNDA for 13–27 kg APDS kids. Priority Review; Jan 30, 2027.
Recent approval for 4–11 y ≥27 kg already granted.
Phase III data in 4–11 y shows reduced lymphadenopathy and increased naive B cells.
PDUFA target date set for January 30, 2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

FDA Accepts sNDA for Lower-Dose Joenja in Young APDS Patients, Jan 2027

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug